Company news
SkinBioTherapeutics PLC news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Research programme with University of Manchester
April 8, 2021
Exercise of Warrant
March 15, 2021
AxisBiotix-PsT food supplement study commences
February 17, 2021
Expanded enrolment for AxisBiotix-PsT study
February 1, 2021
Enrolment for AxisBiotix-PsT study commences
January 13, 2021
Director Dealing
December 4, 2020
Result of General Meeting and Open Offer
October 30, 2020
Placing and Open Offer
October 14, 2020
Grant of Options
September 18, 2020
Appointment of Senior Medical Advisor
September 8, 2020
Product Development Progress
July 31, 2020
Business Update
July 7, 2020
Change of Adviser
June 26, 2020
Half Year Results
March 3, 2020
Agreement signed with Winclove Probiotics B.V.
February 19, 2020
Commercial Agreement
November 20, 2019
Business Update and Board Changes
July 4, 2019
Director Appointment
April 18, 2019
SkinBiotix shows efficacy in first human study
April 8, 2019
CEO Designate Appointment
March 29, 2019
Issue of Equity
February 18, 2019
Half year results
February 14, 2019
Appointment of Joint Broker
February 1, 2019
Update on human study and IP portfolio extension
January 31, 2019
Commencement of final phase of human studies
November 20, 2018
SkinBiotix® generates positive data in human study
November 7, 2018
Human study commenced
September 19, 2018
SkinBiotix technology successful in stability test
September 3, 2018
Provisional ethics approval for human study
July 18, 2018
SkinBioTherapeutics involved in new research grant
May 29, 2018
SkinBioTherapeutics files new patent application
May 14, 2018
SkinBioTherapeutics plans for human study
May 1, 2018
Positive cream formulation results for SkinBiotix
April 17, 2018
SBTX signs MTA with global consumer goods company
April 3, 2018
Notice of Interim Results
February 16, 2018
Notification of first patent grant
December 1, 2017
SkinBiotix platform passes external toxicity tests
November 9, 2017
SkinBioTherapeutics to present at investor evening
November 8, 2017
Cytotoxicity results and scientific update
October 3, 2017
SkinBioTherapeutics to Present at Investor Evening
June 19, 2017
Extension of Research Contract
May 23, 2017
First day of dealings - to trade under SBTX ticker
April 5, 2017
Calls
The 5 newest of 8 calls. Every call is listed under its year.
- SkinBioTherapeutics (LSE:SBTX) — Investor Presentation
Jun 29, 2026
Transcript - SkinBioTherapeutics (LSE:SBTX) — Superdrug Commercial Agreement
Jul 3, 2025
Transcript - SkinBioTherapeutics (LSE:SBTX) — Half Year results for the six months ended 31 December 2024 & Launch
Apr 16, 2025
Transcript - SkinBioTherapeutics (LSE:SBTX) — Full Year Results
Dec 10, 2024
Transcript - SkinBioTherapeutics (LSE:SBTX) — Investor Presentation
Jul 29, 2024
Transcript